Table 1.
Preexistent immunity to peptide HER-2/neu (369–377) in patients with HER-2/neu + tumors. Tetanus toxoid–specific CTL precursor frequencies (PFs) in the same patients (range 1:2,500 to 1:10,800). Peptide (369–377)-specific CTL PFs in patients with HER-2/neu − tumors (<1:85,000) and in healthy individuals (<1:102,700)
| Type of cancer | HLA-allelesa | ||
|---|---|---|---|
| HLA-A2 | HLA-A3 | HLA-A26 | |
| Breast | 1:26,000b | 1:33,500 | 1:57,900 |
| 1:33,000 | 1:39,800 | ||
| 1:37,100 | 1:57,900 | ||
| 1:39,800 | |||
| Colorectal | 1:39,900 | ||
| Lung | 1:45,600 | 1:45,600 | |
| Ovarian | 1:72,150 | ||
| Prostate | 1:35,500 | ||
aPatients carrying one of the indicated alleles exhibited increased peptide-specific CTL precursor frequencies (PF)
bIndicates frequencies of peptide-specific CTL precursors (each sequence corresponds to a single patient tested)